

NOTE: \* No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide.

## ETCTN Lymphoma Trials (Open as of 11/10/2025)

<b>Protocol Number</b>	Phase	Protocol Title
10299	I	A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
10335	I	A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia- Lymphoma (ATLL)
10508	1/11	A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell Lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin lymphoma (HL)
10500	I	Phase 1/Expansion study of tazemetostat plus belinostat for the treatment of relapsed or refractory lymphoma
10590	II	A Phase 2 Study of Mosunetuzumab or Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
10601	I	A Phase 1 Study of Mosunetuzumab with Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
10637	II	Phase 2 Trial of Venetoclax in Classic or Variant Hairy Cell Leukemia
10664	Ib	Phase 1b Study of Combination Tovorafenib and Rituximab Treatment in Relapsed or Refractory Classical Hairy Cell Leukemia and Phase 2 Randomized Study Comparing Tovorafenib and Rituximab with Cladribine and Rituximab for Front-Line Treatment of Classical Hairy Cell Leukemia
10702	II	A Phase II Study of Glofitamab for Relapsed/Refractory Mantle Cell Lymphoma in Patients Previously Treated with CD19-Directed CAR T-Cell Therapy
10717	lb/II	Phase 1b/2 Trial of Pidnarulex in MYC Aberrant Lymphoma
10727	lb	Phase 1b study of teclistamab in relapsed/refractory plasmablastic lymphoma
10760	I	A Phase I Study of Glofitamab with Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma